Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
09/2010
09/21/2010CA2369292C Method of modulating the activity of functional immune molecules
09/21/2010CA2365890C Method for delivering benzindene prostaglandins by inhalation
09/21/2010CA2359948C Triazole compounds with dopamine-d3-receptor affinity
09/21/2010CA2343074C Akt nucleic acids, polypeptides, and uses thereof
09/21/2010CA2307142C N-terminally chemically modified protein compositions and methods
09/21/2010CA2306692C Dipeptide apoptosis inhibitors and the use thereof
09/16/2010WO2010105263A1 Use of hasf as a protective agent against ischemic tissue damage
09/16/2010WO2010105253A2 Methods and compositions for treating complications of diabetes and vascular diseases using flavones
09/16/2010WO2010105081A1 Method of treating heart failure
09/16/2010WO2010104998A2 Methods for treating heart failure by inhibiting the mitochondrial sodium-calcium exchanger (mnce)
09/16/2010WO2010104147A1 Antioxidant agent
09/16/2010WO2010104114A1 Method for preparing polypeptide library
09/16/2010WO2010104024A1 Piperazine compound capable of inhibiting prostaglandin d synthase
09/16/2010WO2010103837A1 Progression inhibitor or prophylactic agent for atherosclerosis, blood cholesterol level-lowering agent, and functional food or food for specified health uses
09/16/2010WO2010103708A1 Dipeptide having antiatherosclerotic action
09/16/2010WO2010103320A1 Use of rosuvastatin lactols as medicaments
09/16/2010WO2010103319A1 Use of atorvastatin lactols as medicaments
09/16/2010WO2010103318A1 Rosuvastatin and atorvastatin derivatives
09/16/2010WO2010103040A1 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
09/16/2010WO2010102937A1 Covalent milk protein/isothiocyanate complexes
09/16/2010WO2010102717A1 Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof
09/16/2010WO2010102554A1 New crystalline form vi of agomelatine, preparation method and application thereof
09/16/2010WO2010102512A1 C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof
09/16/2010WO2010102393A1 2-indolyl imidazo [4,5-d]phenanthroline derivatives and their use to inhibit angiogenesis
09/16/2010WO2010059606A3 Inhibitors of diacylglycerol acyltransferase
09/16/2010WO2010057118A3 Heterocyclic antagonists of prostaglandin d2 receptors
09/16/2010WO2010056910A3 Methods of treating cardiovascular disorders
09/16/2010US20100234599 Method for preparing acid addition salts of polyacidic basic compounds
09/16/2010US20100234467 Methods for improving bioavailability of a renin inhibitor
09/16/2010US20100234464 Compounds for the treatment of metabolic disorders
09/16/2010US20100234461 Compositions For Improved Oxidative Status In Companion
09/16/2010US20100234459 Medicall use of 3-(2,2,2,-trimethylyhdrazinium) propionate hdrogen fumarate and dihydrogen phosephate
09/16/2010US20100234448 In vivo production of small interfering rnas that mediate gene silencing
09/16/2010US20100234443 Combinations of statins and anti-obesity agent
09/16/2010US20100234442 Compositions and Methods for Treatment and Prevention of Cardiovascular Disease
09/16/2010US20100234433 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
09/16/2010US20100234432 Substituted 6-phenylnicotinic acids and their use
09/16/2010US20100234427 1-phenethylpiperidine derivatives and their use as opioid receptor ligands
09/16/2010US20100234406 Compounds and compositions as c-kit and pdgfr kinase inhibitors
09/16/2010US20100234388 Substituted pde5 inhibitors
09/16/2010US20100234386 Quinoxaline derivatives as pi3 kinase inhibitors
09/16/2010US20100234385 Compsition Containing Biopterin and Method for Using The Same
09/16/2010US20100234382 Composition comprising a pde4 inhibitor and a pde5 inhibitor
09/16/2010US20100234380 Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
09/16/2010US20100234377 Piperazine compounds for the inhibition of haematopoietic prostaglandin d synthase
09/16/2010US20100234374 Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors
09/16/2010US20100234370 Pharmaceutical compounds
09/16/2010US20100234369 5-cyanothienopyridines for the treatment of tumours
09/16/2010US20100234365 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
09/16/2010US20100234356 Compounds useful as chemokine receptor antagonists
09/16/2010US20100234355 Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases
09/16/2010US20100234353 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
09/16/2010US20100234352 Factor xa inhibitors
09/16/2010US20100234350 Platelet adp receptor inhibitors
09/16/2010US20100234345 Novel compounds as cannabinoid receptor ligands
09/16/2010US20100234344 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators
09/16/2010US20100234341 Substituted pyrimidines as adenosine receptor antagonists
09/16/2010US20100234335 Neurosteroid compounds
09/16/2010US20100234334 Nitric oxide releasing steroids
09/16/2010US20100234326 Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
09/16/2010US20100234324 Quinazolinamide derivatives
09/16/2010US20100234306 Use of a peptide as a therapeutic agent
09/16/2010US20100234297 Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health
09/16/2010US20100234275 Use Of A High Molecular Weight Extracellular Hemoglobin For The Manufacture Of A Medicament For Treating And/Or Preventing Diseases By Inhibition Of Calcium
09/16/2010US20100233810 In vivo production of small interfering rnas that mediate gene silencing
09/16/2010US20100233735 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
09/16/2010US20100233722 Methods for determining the biological effect and/or activity of r pharmaceutical compositions based on their effect on the methylation status of the DNA
09/16/2010US20100233281 Process for decreasing environmental pollutants in an oil or a fat.
09/16/2010US20100233279 Compositions And Methods Comprising Analogues Of Radicicol A
09/16/2010US20100233263 Methods and compositions for treatment of lesioned sites of body vessels
09/16/2010US20100233261 Pharmaceutical Composition Comprising Amlodipine and Losartan
09/16/2010US20100233256 Synergistic combinations for treating hypertension
09/16/2010US20100233255 Combination of trazine derivatives and insulin secretion stimulators
09/16/2010US20100233253 Extended release gastro-retentive oral drug delivery system for valsartan
09/16/2010US20100233235 Compositions and methods for preventing cardiac arrhythmia
09/16/2010US20100233228 Drug-Eluting Medical Device
09/16/2010US20100233227 Medical devices having carbon drug releasing layers
09/16/2010US20100233179 BAFF, inhibitors thereof and their use in the modulation of B-cell response
09/16/2010US20100233177 Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
09/16/2010US20100233169 Methods for treating obesity using fibroblast growth factor-Like polypeptides
09/16/2010US20100233168 Rationale for IL-1 Beta targeted therapy in sickle cell disease for ischemia-reperfusion induced complications
09/16/2010US20100233159 Methods of treating stroke
09/16/2010US20100233158 Induction of immune tolerance
09/16/2010US20100233155 Humanized anti-ccr2 antibodies and methods of use therefor
09/16/2010US20100233154 Targeted binding agents directed to heparanase and uses thereof 463
09/16/2010US20100233153 Novel gene disruptions, compositions and the methods relating thereto
09/16/2010US20100233143 Parthenogenic Activation of Human Oocytes for the Production of Human Embryonic Stem Cells
09/16/2010US20100233135 Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis
09/16/2010US20100233116 Organic compounds
09/16/2010US20100233088 Method of identifying strategies for treatment or prevention of ventricular fibrilation and ventricular tachycardia
09/16/2010US20100233083 Microparticles comprising a crosslinked polymer
09/16/2010US20100233079 Dual Variable Domain Immunoglobulins and Uses Thereof
09/16/2010DE102009012314A1 Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung Oxo-heterocyclic-substituted alkyl carboxylic acids and their use
09/16/2010CA2755396A1 Use of hasf as a protective agent against ischemic tissue damage
09/16/2010CA2755117A1 Substituted fused pyrimidine compounds
09/16/2010CA2754825A1 Use of rosuvastatin lactols as medicaments
09/16/2010CA2754787A1 Use of atorvastatin lactols as medicaments
09/16/2010CA2754613A1 Piperazine compound capable of inhibiting prostaglandin d synthase
09/16/2010CA2754562A1 Rosuvastatin and atorvastatin derivatives
09/16/2010CA2754542A1 Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof
1 ... 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 ... 1595